Published in Br J Cancer on February 01, 1996
The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46
Rapid repair of UVA-induced oxidized purines and persistence of UVB-induced dipyrimidine lesions determine the mutagenicity of sunlight in mouse cells. FASEB J (2008) 0.91
Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. Br J Cancer (1996) 0.79
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68
A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00
p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature (1994) 10.95
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06
Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet (1994) 4.63
Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science (1992) 2.89
Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci U S A (1994) 2.64
p16 gene in uncultured tumours. Nature (1994) 2.47
Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (1994) 2.16
Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res (1994) 1.80
S26 ribosomal protein RNA: an invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res (1993) 1.77
High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med (1985) 1.51
Mutational analysis of CDKN2 (MTS1/p16ink4) in human breast carcinomas. Cancer Res (1994) 1.29
Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res (1994) 1.15
Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet (1993) 1.08
Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. Am J Pathol (1995) 0.95
Manifold sequencing: efficient processing of large sets of sequencing reactions. Proc Natl Acad Sci U S A (1994) 0.90
Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res (2000) 4.66
The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst (1996) 2.57
European Code Against Cancer and scientific justification: third version (2003). Ann Oncol (2003) 2.17
Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol (1998) 2.09
Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci U S A (1993) 2.08
Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities. Swedish Melanoma Study Group. J Clin Oncol (1991) 2.02
Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst (1997) 1.91
Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine. Lancet (1993) 1.87
Nucleolar-derived ribonucleic acid in chromosomes, nuclear sap, and cytoplasm of Chironomus tentans salivary gland cells. J Cell Biol (1971) 1.51
Cutaneous malignant melanoma of the head and neck. Analysis of treatment results and prognostic factors in 581 patients: a report from the Swedish Melanoma Study Group. Cancer (1993) 1.46
Perceptions of the effectiveness of ethical guidelines: an international study of physicians. Med Health Care Philos (2009) 1.41
Chimeric IgG-binding receptors engineered from staphylococcal protein A and streptococcal protein G. J Biol Chem (1988) 1.33
Second primary cancers in patients with squamous cell carcinoma of the skin: a population-based study in Sweden. Int J Cancer (1999) 1.28
Anti-IgE antibodies in human serum: occurrence and specificity. Int Arch Allergy Appl Immunol (1981) 1.26
Ultraviolet-induced dna repair synthesis in lymphocytes from patients with actinic keratosis. J Invest Dermatol (1976) 1.22
A follow-up study of children with food allergy. Clinical course in relation to serum IgE- and IgG-antibody levels to milk, egg and fish. Clin Allergy (1981) 1.22
Prognostic value of p53 genetic changes in colorectal cancer. J Clin Oncol (1999) 1.20
Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: clinical observations and histopathologic features. Cancer (1999) 1.20
PCR-based genotyping for duplicated and deleted CYP2D6 genes. Pharmacogenetics (1996) 1.17
In situ demonstration of DNA hybridizing with chromosomal and nuclear sap RNA in Chironomus tentans. J Cell Biol (1972) 1.17
Cytoplasmic and nuclear accumulation of beta-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int J Cancer (2001) 1.15
N-ras mutations are common in melanomas from sun-exposed skin of humans but rare in mucosal membranes or unexposed skin. J Invest Dermatol (1998) 1.15
Further evidence for increased light sensitivity in patients with malignant melanoma. Br J Dermatol (1981) 1.14
Malignant melanoma of the vulva and vagina. Trends in incidence, age distribution, and long-term survival among 245 consecutive cases in Sweden 1960-1984. Cancer (1993) 1.13
Second primary cancers in patients with cutaneous malignant melanoma: a population-based study in Sweden. Br J Cancer (1996) 1.13
Malignant melanoma: aetiological importance of individual pigmentation and sun exposure. Br J Dermatol (1990) 1.13
Comparison of mechanisms of interaction between protein A from Staphylococcus aureus and human monoclonal IgG, IgA and IgM in relation to the classical FC gamma and the alternative F(ab')2 epsilon protein A interactions. Scand J Immunol (1981) 1.11
Chromosomal RNA synthesis in polytene chromosomes of Chironomus tentans. Chromosoma (1969) 1.11
Comparison between p53 protein measurements using the luminometric immunoassay and immunohistochemistry with detection of p53 gene mutations using cDNA sequencing in human breast tumors. Int J Cancer (1998) 1.09
Intestinal uptake of ovalbumin in malabsorption and food allergy in relation to serum IgG antibody and orally administered sodium cromoglycate. Clin Allergy (1979) 1.09
Increasing incidence rates of squamous cell carcinoma of the skin in Sweden. Acta Derm Venereol (2001) 1.08
The Rb1 fraction of ginseng elicits a balanced Th1 and Th2 immune response. Vaccine (2005) 1.06
CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Cancer Res (2000) 1.05
Expression of class Pi glutathione transferase in human malignant melanoma cells. Carcinogenesis (1987) 1.05
Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol (1989) 1.03
Trends in the incidence of malignant melanoma in Sweden, by anatomic site, 1960-1984. Am J Epidemiol (1990) 1.03
Worse survival for TP53 (p53)-mutated breast cancer patients receiving adjuvant CMF. Ann Oncol (2005) 1.02
Interaction of human polyclonal IgE and IgG from different species with protein A from Staphylococcus aureus: demonstration of protein-A-reactive sites located in the Fab'2 fragment of human IgG. Scand J Immunol (1980) 1.02
Flow cytofluorometric DNA analyses of metastases of human malignant melanomas. Anal Quant Cytol (1982) 1.01
Serum S-100b protein as a prognostic marker in malignant cutaneous melanoma. J Clin Oncol (2001) 1.00
Extraction and fractionation of low molecular weight RNA on the microscale. Nature (1968) 0.99
RNA synthesis in a Balbiani ring in Chironomus tentans salivary gland cells. Chromosoma (1969) 0.98
Age-related decrease of ultraviolet light-induced DNA repair synthesis in human peripheral leukocytes. Cancer Res (1979) 0.97
O6-methylguanine-DNA-methyltransferase expression and gene polymorphisms in relation to chemotherapeutic response in metastatic melanoma. Br J Cancer (2003) 0.97
Low molecular weight RNA in cell components of Chironomus tentans salivary glands. J Mol Biol (1969) 0.96
Electrophoretic characterization of nucleolar RNA from Chironomus tentans salivary gland cells. J Mol Biol (1970) 0.96
Interferon therapy in Hodgkin's disease. A case report. Acta Med Scand (1976) 0.96
Cancer risk in patients with earlier diagnosis of cutaneous melanoma in situ. Int J Cancer (1999) 0.96
Normal UV-induced DNA repair synthesis in peripheral leukocytes from patients with malignant melanoma of the skin. J Invest Dermatol (1980) 0.94
Prognostic value of P53 gene mutations in a large series of node-negative breast cancer patients. Cancer Res (1998) 0.94
Sensitization of human melanoma cells to the cytotoxic effect of melphalan by the glutathione transferase inhibitor ethacrynic acid. Cancer Res (1991) 0.93
p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings. J Clin Oncol (1995) 0.93
Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: randomized study by the Swedish Melanoma Study Group. Cancer (1996) 0.93
Leukaemia, leukaemoid reaction and tuberculosis. Acta Med Scand (1967) 0.93
Correlation of findings at barium enema examination, rectoscopy and biopsy of rectum. Acta Radiol Diagn (Stockh) (1966) 0.92
A case report including EM and DNA repair investigations in a dermatosis associated with multiple skin cancers: epidermodysplasia verruciformis. Acta Med Scand (1976) 0.92
Evidence for transport of preribosomal RNA from the nucleolus to the chromosomes in Chironomus tentans salivary gland cells. J Mol Biol (1970) 0.92
Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res (1987) 0.92
The frequency and distribution of mitotic figures in dysplasia and carcinoma in situ. Cancer (1977) 0.91
Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets. Clin Chem (1998) 0.91
The association between anatomic site and survival in malignant melanoma. An analysis of 12,353 cases from the Swedish Cancer Registry. Eur J Cancer Clin Oncol (1989) 0.90
Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial. Eur J Cancer (1998) 0.89
Contribution of glutathione transferase M3-3 to 1,3-bis(2-chloroethyl)-1-nitrosourea resistance in a human non-small cell lung cancer cell line. Cancer Res (1993) 0.89
Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma. Acta Oncol (1999) 0.89
Analysis of O(6)-methylguanine-DNA methyltransferase in melanoma tumours in patients treated with dacarbazine-based chemotherapy. Melanoma Res (2002) 0.88
Novel O6-methylguanine-DNA methyltransferase SNPs: a frequency comparison of patients with familial melanoma and healthy individuals in Sweden. Hum Mutat (2002) 0.88
Central nervous system metastases of cutaneous malignant melanoma--a population-based study. Acta Oncol (1998) 0.87
Intracellular distribution of low molecular weight RNA in Chironomus tentans. J Cell Biol (1971) 0.86
Perceived susceptibility to and knowledge of malignant melanoma: screening participants vs the general population. Prev Med (1997) 0.86
Phy-sico-chemical properties of chromosomal RNA in Chironomus tentans polytene chromosomes. Chromosoma (1969) 0.86
Penetrances of BRCA1 1675delA and 1135insA with respect to breast cancer and ovarian cancer. Am J Hum Genet (1999) 0.86
Prognostic value of serum analyses of S-100 beta protein in malignant melanoma. Melanoma Res (1996) 0.86
Outcomes of patients with local recurrence of cutaneous malignant melanoma: a population-based study. Cancer (1997) 0.86
Psychological reactions in patients with malignant melanoma. Eur J Cancer (1995) 0.85
A method for estimation of circulating immune complexes after oral challenge with ovalbumin. Clin Allergy (1980) 0.85
Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study. Int J Cancer (1998) 0.85
Treatment of keloids with surgical excision and postoperative X-ray radiation. Scand J Plast Reconstr Surg Hand Surg (1989) 0.85
Prevalence of primary acquired melanosis and nevi of the conjunctiva and uvea in the dysplastic nevus syndrome. A case-control study. Ophthalmology (1995) 0.84
Trends in survival from malignant melanoma: remarkable improvement in 23 years. J Natl Cancer Inst (1989) 0.84
Immunohistochemical analysis of the N-ras p21 and the p53 proteins in naevi, primary tumours and metastases of human cutaneous malignant melanoma: increased immunopositivity in hereditary melanoma. Melanoma Res (1995) 0.84
Malignant melanoma of the vulva in a nationwide, 25-year study of 219 Swedish females: predictors of survival. Cancer (1999) 0.84
Increase of uv-induced DNA repair synthesis during blast transformation of human lymphocytes. Exp Cell Res (1979) 0.84
Immunohistochemical examination of the expression of O6-methylguanine-DNA methyltransferase in human melanoma metastases. Eur J Cancer (1997) 0.84
Trends in mortality from malignant melanoma in Sweden, 1970-1996. Cancer (2000) 0.83
Induction and time course of DNA single-strand breaks in lymphocytes from patients treated with dacarbazine. Carcinogenesis (1991) 0.83
O6-methylguanine-DNA methyltransferase activities in biopsies of human melanoma tumours. Br J Cancer (1995) 0.83
Interaction of polyclonal human IgE with protein-A from Staphylococcus aureus. Immunol Rev (1978) 0.83
Seasonal variation in ethylene concentration in the wood of Pinus sylvestris L. Tree Physiol (1991) 0.83
Localization of newly synthesized low molecular weight RNA in polytene chromosomes from Chironomus tentans. Chromosoma (1971) 0.83
Melanoma metastases from patients with hereditary cutaneous malignant melanoma contain a high frequency of N-ras activating mutations. Melanoma Res (1994) 0.82
Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors. J Natl Cancer Inst (1987) 0.82